Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

arVax(TM). The objective of the Phase II study was to evaluate safety, tolerability and immunogenicity of SparVax(TM) and to compare it to the licensed vaccine, BioThrax(R), which was administered in accordance with the then approved vaccination route and regimen for general use in prophylaxis against anthrax. A total of 226 healthy male and female volunteers, age 18-55, were enrolled in the trial which was conducted at 16 sites in the United States.

The subjects were randomized to receive either three doses of BioThrax(R) or SparVax(TM) (at one of two dose levels followed by an antigenic challenge dose, i.e., a dose to show that the initial series of doses adequately "primed" the immune system to respond to natural infection by producing antibody due to immunologic memory.) The three dose groups were: 50 Microgram SparVax on Days 0, 28 and 56 (n = 91); 100 Microgram SparVax on Days 0, 28 and 56 (n = 92), and; 0.5 mL BioThrax(R) on Days 0, 14, and 28 (n = 43). At day 182, subjects receiving SparVax(TM) were re-randomized to a challenge at the original dose, on either day 182 or 364. The antigenic challenge dose (50 or 100 Microgram) each subject received was the same as the dose assigned to that subject during the initial vaccination schedule. Safety and immunogenicity were assessed throughout the study.

BioThrax(R) subjects were allowed to complete the full course of treatment, but data were not collected from these subjects after Day 70. Subjects who continued in the study were followed up for 18 months (Day 546) from the original vaccine dose.

Study results showed that there were an increased proportion of individuals experiencing injection site pain in the BioThrax(R) group as compared to the SparVax(TM) groups at both dose levels. There were no notable differences between the SparVax(TM) groups and the BioThrax(R) group regarding safety laboratory values, vital signs and ECG results. Additionally, in th
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Investor-Edge has initiated coverage on ... Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics Inc. ... MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free ... http://investor-edge.com/register . On Wednesday, October 29, ... the Dow Jones Industrial Average declined 0.18%, to finish ...
(Date:10/30/2014)... UK (PRWEB) October 29, 2014 Global ... of the world economic crisis during 2008-2009, especially in ... has recovered and currently is keeping to a growing ... output volume is utilized in the construction segment. In ... of pipes, profiles, tubing, sheets and rigid film. Moreover, ...
(Date:10/30/2014)... On October 26th at the Mid ... leading applied stem cell research scientist Neil Riordan, ... talks on New Techniques for Enhancing Stem Cell ... Cells. , Dr. Riordan focused on historical medical ... AlphaGEMS that include: wound healing; inflammation and pain ...
(Date:10/30/2014)... 2014 Rancho BioSciences , the ... manually curated public data source TCGA for ... the data is now available for other oncology groups. ... and internal data sources for their Pharma, Government and ... the data that becomes more easily accessible. Rancho ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Rancho BioSciences Manually Curated TCGA Data Sets Available 2
... leading innovator in the development and commercialization of sensing systems ... (CBRNE) materials, today announced a media awareness initiative for JMAR,s ... online system for real-time detection of pathogens in water. ... ...
... release of GridGain 2.1 - the next version of its innovative ... ... January 13, 2009 -- GridGain Systems is proud to ... its innovative Java-based Open Cloud Platform. GridGain 2.1 provides the industry ...
... Coronary StentForms Alliance to Jointly Develop Drug Eluting ... announced today that that the company entered into ... incorporated subsidiary of Opto Circuits (OCI) Ltd., by ... Maxcor,s Genius MAGIC Cobalt Chromium Coronary Stent System ...
Cached Biology Technology:JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism 2JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism 3JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism 4GridGain 2.1 - Open Cloud Platform Enables Development of Native Cloud Applications 2GridGain 2.1 - Open Cloud Platform Enables Development of Native Cloud Applications 3Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons 2Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons 3
(Date:10/31/2014)... in cities is good for attracting species, but it may ... University of Iowa study has found. , The researchers surveyed ... and recorded the abundance of two insects that interact with ... trees, black cherry and black walnut, they didn,t find a ... that feed on the walnuts and black cherries and a ...
(Date:10/31/2014)... been studying the behavior of approximately 300 wild ... They observed that ravens slowly build alliances through ... they also observed that these affiliative interactions were ... about 50 % of the cases these interventions ... ravens, intervening can be potentially risky when the ...
(Date:10/30/2014)... LANSING, Mich. – When most animals begin life, cells ... or a vital organ. However, mammals, including humans, are ... a different first choice – to become the protective ... It,s during this critical first step that research from ... published in the current issue of PLOS ...
Breaking Biology News(10 mins):Green spaces don't ensure biodiversity in urban areas 2Identifying the source of stem cells 2
... Nelson Laboratories ( www.nelsonlabs.com ) will offer free ... in San Jose, CA ... Those interested in a consultation should register at ... Rollins will also present, "Selection, Testing and Validation ...
... Wilhoit and Timothy Coolong from the University of Kentucky ... application of organic mulches more efficient. The research team ... in the August issue of HortTechnology . The ... to document its efficiency. "We modified an unroller so ...
... Why do crosses between closely related species fail to ... Axel Imhof of Ludwig-Maximilians-Universitaet (LMU) in Munich shows that ... - of certain key proteins are crucial in mediating ... to the same biological species, if matings between them ...
Cached Biology News:Nelson Laboratories to Offer Free Biocompatibility Consultations During BIOMEDevice San Jose 2New bale unroller design deemed effective 2Origin of species: Protein imbalances doom hybrids 2
... dUTPase The thermostable dUTPase(pyrococcus ... PCR (using proofreading DNA polymerases). ... PCR reactions and dNTP solutions. ... proofreading DNA polymerase reaction can prevent ...
... an exciting product for cell-based kinetic assays ... the use of expensive HTS equipment, which ... the assay development stage. The NOVOstar offers ... as well as any other assay suitable ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Open-slot design for easy cleaning. ...
... Agilent Technologies introduces an enhanced ... ICP-MS for Windows 2000 and ... From September 2003, all new ... controlled by the new ChemStation ...
Biology Products: